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1. Introduction 
A lot of fruits contain nutrient substances that can prevent, cure or suppress various 
diseases. They are nature’s true medicines, and diets rich in fruits are consistently 
associated with a decreased risk of cancer and other chronic diseases. Apricot “Prunus 
armeniaca” is the fruit of a rosaceous tree (rosaceae), which is produced in most parts of the 
world (Gur, 1985). The name Prunus armeniaca is thought to be a misnomer based upon 
the long-held view that apricots initially originated in Armenia. It is known that apricots 
originated in the Far East, most likely in the Himalayas, the Northern and Western 
regions of China from where they spread to Armenia and Russia (Gu, 1979; Gulcan, 1988). 
Apricot is found semi-wild and wild in the northern hills of China and in a broad belt 
across the hills, mountains, and plateaus of Central Asia as far as the Caucasus 
Mountains. The first record of the domestication of apricots is an account of their 
cultivation in China, about 4000 years ago. It is likely that tribe people of Central Asia 
established traditional rights to harvest their parts of the apricot forests for millennia 
before this time. 
The apricot variety found in Japan is “Prunus mume Sieb. et Zucc’’ widely known as Ume 
(Figure 1). The Japanese people started to grow Ume trees more than 2000 years ago, most 
likely imported from China. Soon they discovered the health enhancing effects of apricot 
fruits, and over many centuries, through cultivation, they have improved their apricot tree 
variety to produce healthier fruits. Accordingly, there is a long-standing view that the 
Japanese apricot juice can suppress cancer in tumour bearing hosts and inhibit the growth of 
bacteria. 
This article reviews the current knowledge on Ume, including its correlation with some 
diseases and periodontitis. 
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Fig. 1. MK615 is made from Japanese apricot (Ume). 
2. Anti-cancer effects of an extract from Ume  
MK615 is an extract mixture containing hydrophobic substances from Ume (AdaBio, 
Gunma, Japan) (Figure 1). It contains several triterpenoids and has been shown to exert an 
anti-neoplastic effect against human cancers, such as breast cancer, stomach cancer, 
hepatocellular carcinoma, colon cancer and malignant melanoma. The mechanisms 
responsible for the anti-neoplastic effects of MK615 include induction of apoptosis and 
autophagy, and suppression of Aurora A kinase in cancer cells (Nakagawa et al., 2007; 
Adachi et al., 2007; Okada et al., 2007; Mori et al., 2007; Matsushita et al., 2010). 
3. Inhibitory effects of an extract from Ume on Helicobacter pylori 
Helicobacter pylori infection is an important factor in human gastric disorders, including 
chronic active gastritis, peptic ulcers, intestinal metaplasia and cancer. 
In the in vitro study, Ume extract had an immediate bactericidal effects on H. pylori 
(Miyazawa et al., 2006; Enomoto et al., 2010). In the in vivo study, Ume extract suppress 
chronic active gastritis in the glandular stomachs of H. pylori-infected Mongolian gerbils 
(Otsuka et al., 2005). H. pylori-inoculated gerbils were given Ume extract in their drinking 
water for 10 weeks. The microscopic scores for gastritis and mucosal hyperplasia in the Ume 
extract groups were significantly lower than in the H. pylori-inoculated control group, with 
dose-dependence. Additionally, it was reported that Ume extract showed the antibacterial 
effect on H. pylori in the human stomach in vivo pilot study (Nakajima et al., 2006). 
Therefore, Ume extract may have potential as a safe and inexpensive agent to control H. 
pylori-associated gastric disorders, including gastric neoplasia. 
4. Anti-inflammatory effects of an extract from Ume 
The high mobility group box 1 protein (HMGB1), a nuclear protein, has two distinct 
functions in cellular systems. In the nucleus, HMGB1 acts as an intracellular regulator of the 
transcription process with a crucial role in the maintenance of DNA functions (Lu et al., 
1996). In the extracellular space, HMGB1 is released by all eukaryotic cells upon necrosis or 
by various cells in response to inflammatory stimuli such as endotoxins, tumor necrosis 
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factor (TNF)- α, and C-reactive protein (Wang et al., 1999; Taniguchi et al., 2003; Kawahara 
et al., 2008). Extracellular HMGB1 can act as a potent inducer of proinflammatory cytokines 
including TNF- α, interleukin (IL)-6, and IL-1s from a wide variety of cells, thus playing a 
major role in various inflammatory diseases such as sepsis, rheumatoid arthritis, 
disseminated intravascular coagulation, periodontitis, xenotransplantation and 
atherosclerosis (Wang et al., 1999; Taniguchi et al., 2003; Kawahara et al., 2008; Ito et al., 
2007; Morimoto et al., 2008; Kawahara et al., 2007; Porto et al., 2006). Therefore, agents 
capable of inhibiting HMGB1 can be considered to possess therapeutic potential. 
It was reported that an extract of Ume, an abundant source of triterpenoids, strongly 
inhibited HMGB1 release from lipopolysaccharide (LPS)-stimulated macrophage-like 
RAW264.7 cells (Kawahara et al., 2009). The inhibitory effect on HMGB1 release was 
enhanced by authentic oleanolic acid (OA), a naturally occurring triterpenoid. Similarly, the 
HMGB1 release inhibitor in Ume extract was found to be OA. Regarding the mechanisms of 
the inhibition of HMGB1 release, the OA or Ume extract was found to activate the 
transcription factor Nrf2, which binds to the antioxidative responsive element, and 
subsequently the heme oxygenase (HO)-1 protein was induced, indicating that the 
inhibition of HMGB1 release from LPS-stimulated RAW264.7 cells was mediated via the 
Nrf2/HO-1 system; an essentially antioxidant effect. These results suggested that natural 
sources of triterpenoids warrant further evaluation as ‘rescue’ therapeutics for sepsis and 
other potentially fatal systemic inflammatory disorders. 
5. Periodontal disease 
5.1 Symptoms 
Periodontal disease, which includes gingivitis and periodontitis, is the most common 
chronic disorder of infectious origin known in humans, with a prevalence of 10–60% in 
adults depending on the diagnostic criteria used (Papapanou, 1996). Periodontitis is a 
chronic inflammatory disease of which the primary etiological factor is microbial dental 
plaque which causes an inflammatory response (Loe et al., 1965). Periodontitis destroys the 
periodontal tissue and eventually causes loss of teeth . Chronic and progressive bacterial 
infection leads to gingival connective tissue destruction and irreversible alveolar bone 
resorption (Ranny, 1993). Periodontal disease has various states and stages, ranging from 
easily treatable gingivitis to irreversible severe periodontitis and is increased by several risk 
factors such as systemic disease, medications (hypotensors, anti-epilepsy drugs and anti-
cancer drugs), cigarette smoking, ill-fitting bridges, and trauma caused by occlusion 
(Papapanou, 1996; Slavin & Taylor, 1987; Grossi et al., 1997; Bjorn et al., 1969; Glickman, 
1965). In addition to these variables, medical conditions that trigger host antibacterial 
defense mechanisms, such as neutrophil disorders and human immunodeficiency virus 
(HIV) infection, are likely to promote periodontal disease (Clark et al., 1977; Mealey, 1996). 
The most prevalent form of periodontal disease is a mild form called gingivitis. Gingivitis is 
characterized by inflammation of the gums, redness, swelling, and frequent bleeding on 
probing (Greenstein, 1984). More advanced forms of periodontitis are also prevalent. The 
symptoms are similar to those of gingivitis, but are more severe due to the stronger 
inflammatory responses. Periodontitis is characterized by loss of gingival connective tissue 
attachments and alveolar bone resorption. 
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For diagnosing the extent of periodontal disease, probing depth is a good indicator of how 
far the disease has advanced (Greenstein, 1997). In clinically healthy periodontium, there is 
no apical migration of epithelial attachment or pocket formation and the probing depth is 1-
3 mm . Patients with probing depths of 4 mm or more are diagnosed with periodontitis. 
Patients with probing depths of 6 mm or more are diagnosed with advanced, or severe 
periodontitis. Due to mild nature of symptoms, such as gingival bleeding and attachment 
loss many individuals neglect to treat their disease which, if left untreated, may progress to 
irreversible periodontitis and eventually tooth loss. 
5.2 Pathogenesis of periodontal disease 
The presence of large numbers of oral bacteria can induce tissue destruction indirectly by 
activating host defense cells, which in turn, release mediators that stimulate the effectors of 
connective tissue destruction. The components of microbial plaques have the capacity to 
induce an initial infiltrate of inflammatory cells that includes lymphocytes, macrophages, 
and polymorphonuclear leukocytes (PMNs) (Kowashi et al., 1980; Zappa et al., 1991). 
Microbial components, especially LPS, activate macrophages, which synthesize and secrete 
a variety of proinflammatory mediators including IL-1, IL-6, IL-8, TNF-α, prostaglandin E2 
(PGE2) and hydrolytic enzymes (Birkedal-Hansen, 1993). Similarly, bacterial substances 
induce T lymphocytes to produce IL-1 and lymphotoxin (LT), a molecule with similar 
properties to TNF-α. These cytokines play a key role in periodontal tissue destruction 
through the induction of collagenolytic enzymes such as matrix metalloproteinases (MMPs) 
(Sorsa et al., 1992). These latent collagenolytic enzymes are activated by reactive oxygen 
species in the inflammatory environment, leading to elevated levels of interstitial 
collagenase in inflamed gingival tissue.  
5.3 Periodontal disease and systemic disease 
In the last decade, many studies have been published indicating a positive relationship 
between periodontal disease and various systemic diseases. Significant associations between 
periodontal disease and cardiovascular disease, diabetes mellitus, preterm low birth weight 
and osteoporosis have been reported (Jemin, & Salomon, 2006), bridging the once wide gap 
between medicine and dentistry. Researchers have hypothesized the etiologic role of 
periodontitis in the pathogenesis of these systemic diseases. Therefore, patients diagnosed 
with periodontal disease may be at a higher risk due to a compromised immune system as 
infectious and opportunistic microbes responsible for periodontal infection may prove a 
burden to the rest of the body. Furthermore, these microbes can release products that elicit an 
inflammatory response. Periodontal lesions are recognized as continually renewing reservoirs 
for the systemic spread of bacterial antigens, Gram-negative bacteria, cytokines and other 
proinflammatory mediators. Therefore,  development of new treatment modalities for 
periodontitis may contribute to the effective inhibition of systemic inflammatory diseases. 
5.4 Treatment of periodontal disease 
Once diagnosed, most periodontal diseases can be treated successfully. Therapeutic goals 
are to eliminate bacteria and other contributing risk factors, thereby preventing  progression 
of the disease and maintaining healthy state of  periodontal tissues. The recurrence of 
periodontitis must also be prevented. In severe cases, regeneration of the periodontal 
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attachment must be attempted. The nonsurgical step involves a special cleaning technique 
called scaling and root planing. Supplemental treatment tools may include an antiseptic 
mouth rinse and other medications, either to aid the healing process, to suppress 
inflammation, or to further control the bacterial infection. Often, antibiotics are 
administered. Tetracyclines, or a combination of amoxicillin and metronidazole, may be 
used to kill a broad range of bacteria in microbial dental plaque(Hayes et al., 1992; Van 
Winkelhoff et al., 1992). However, if overused, these agents may become uneffective. 
Another drawback to antibiotic therapy lies in the difficulty of identifying and targeting a 
specific pathogen due to the numerous species residing in the plaque.  
6. Possible new treatments for periodontitis 
6.1 Anti-inflammatory effects of an extract from Ume  
Natural compounds such as catechins in green tea, naringenin, a major flavanone, in 
grapefruits, and polyphenols in cranberries may be useful for the prevention and treatment of 
inflammatory periodontal diseases (Makimura et al., 1993; Bodet et al., 2008; Bodet et al., 2008). 
Consequently, natural compounds with the capacity to modulate host inflammatory responses 
have received considerable attention, with the suggestion that they may be potential new 
therapeutic agents for the treatment of periodontal disease (Paquette & Williams, 2000). Some 
studies indicate that MK615 extracted from Ume may have not only anti-cancer effects, but also 
strong anti-inflammatory effects. MK615 contains several triterpenoids, including oleanolic 
acid and ursolic acid, and may have anti-inflammatory effects. Recent studies have suggested 
that triterpenoids have both anti-tumor and anti-inflammatory effects (Nakagawa et al., 2007; 
Adachi et al., 2007; Okada et al., 2007; Okada et al., 2008; Kawahara et al., 2009). MK615 
inhibits the release of HMGB1, a novel inflammatory mediator, by LPS-stimulated RAW264.7 
cells (Kawahara et al., 2009). The inhibitory mechanism is mediated via the antioxidant 
compounds heme oxygenase-1, NQO-1 and glutathione-s transferase, which are induced by 
oleanolic acid. This strongly suggests that MK615 may suppress inflammation. 
In the periodontal field, MK615 inhibits cytokine release, including that of TNF-α and IL-6, 
by P. gingivalis LPS-stimulated cells in dose-dependent manners (Morimoto et al., 2009). It is 
clearly indicating that MK615 contains an inhibitor of cytokine release. The continuous high 
secretion of various cytokines including TNF-α and IL-6 by host cells following stimulation 
with periodontal pathogens and their products is a critical determinant of periodontal tissue 
destruction. Therefore, blockade of TNF-α and IL-6 secreted by periodontal pathogens or 
other cytokines may suppress pro-inflammatory responses, and inhibit the development 
and progression of periodontal disease. It has been reported that LPS possibly induces TNF-
α and IL-6 expressions through transient phosphorylation of ERK1/2, JNK, and p38MAPK 
(Matsuzaki et al., 2004; Kim et al., 2007; Son et al., 2008; Neuder et al., 2009; Xiao et al., 2007). 
Additionally, it has been also reported that the production of inflammatory cytokines 
requires nuclear factor kappaB (NF-κB) activation (D’Acquisto et al., 1997). The inhibitory 
mechanism of MK615 is mediated by the attenuation of MAPK phosphorylation (Figure 2) 
and subsequent inactivation of NF-κB to suppress LPS-induced translocation and 
phosphorylation of the p65 subunit (Figure 3 &4). These results support the notion that 
MK615 has anti-inflammatory effects, and MK615 may represent a key molecule with 
therapeutic potential for periodontitis. Therapeutic approaches that inhibit cytokine 
production are receiving increasing attention as options for managing chronic periodontitis.  
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Fig. 2. MK615 inhibits phosphorylation of MAPKs. 
 
Fig. 3. MK615 suppresses NF-κB activation but not degradation of IκB. 
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Fig. 4. MK615 suppresses P. gingivalis LPS-induced nuclear translocation of NF-κB p65 in 
RAW264.7 cells. Cells were left untreated or pretreated with MK615 and stimulated with 
LPS. (A) In untreated cells, NF-κB p65 is limited to the cytoplasm. (B) LPS-stimulated cells 
show NF-κB p65 (green) translocation into the nucleus. (C) LPS-stimulated cells pretreated 
with MK615 show a significant reduction in p65 nuclear translocation. (D) Cells treated with 
MK615 alone show no effect. Cells stained with DAPI were used to verify the nuclear 
localization (blue). Original magnification: ×400. 
6.2 Anti-microbial effects of an extract from Ume  
Periodontitis and dental caries are major oral diseases. The formation of dental plaque, 
which plays an important role in the development of periodontal disease and caries in 
humans, can be initiated by several strains of oral streptococci (Freedman & Tanzer, 1974; 
Tanzer et al., 1974). Streptococcus mutans is the main pathogen for dental caries, although 
other acidogenic microorganisms can also be involved (Murata, 2008). S. mutans produces 
three types of glucosyltransferase (GTFB, GTFC and GTFD), and synthesizes an adherent 
and water-insoluble glucan from sucrose that allows adherence of S. mutans to the tooth 
surface and dental plaque formation (Edwardsson, 1968; Hamilton-Miller, 2001). 
There is great interest in the use of antimicrobial agents for the prevention and treatment of 
periodontitis and caries. The prevention of periodontal disease and dental caries requires 
control of the pathogens that exist in the oral dental plaque biofilm. Chlorhexidine is a 
potent antiplaque chemical agent. However, it has some side effects, such as altered taste 
sensation, desquamation and soreness of the oral mucosa (Makimura et al., 1993). Thus, it is 
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It is reported that MK615 has not only anti-inflammatory effects for periodontal tissues but 
also antimicrobial activity against periodontal bacteria, such as A. actinomycetemcomitans and 
P. gingivalis (Table 1). In addition, MK615 exerted antibacterial activity against cariogenic 
bacteria, such as S. mutans, S. gordonii and S. sanguinis, with an expected anti-caries effect 
(Table 1). Moreover, it was found that MK615 exhibited an inhibitory effect on S. mutans 
biofilm formation. The most effective treatment against dental caries and periodontitis 
would be one that prevents early biofilm formation (Wei et al., 2006). MK615 is known to 
contain active components with anti-inflammatory and anti-oxidative properties, such as 
oleanolic acid (Kawahara et al., 2009). A previous study suggested that oleanolic acid has 
antimicrobial actions against S. mutans (Kozai et al., 1999), while another study showed that 
oleanolic acid markedly inhibits water-insoluble glucan synthesis from sucrose by the crude 
glucosyltransferase of S. mutans (Kozai et al., 1987). Therefore, MK615 has potential as a 
therapeutic agent for treating and preventing oral diseases such as periodontitis and dental 
caries. Further studies will focus on the active antimicrobial components in MK615, which 
should be identified and investigated for their mechanisms of action. Additionally, further 
studies are required to investigate the effects of local application of MK615 as an adjunctive 
treatment to conventional therapy for patients with periodontitis. Such studies may lead to 
the development of novel periodontal therapies and improved strategies for public oral 
health. 
 
MICs of MK615 against oral 
microorganisms. 
 
   
Species (mg/ml)  
A. actinomycetemcomitans 57 6.5  
A. actinomycetemcomitans IDH 6.5  
P. gingivalis 1.6  
S. mutans UA159 13  
S. mutans MT403R 13  
S. mutans RIMD 13  
S. gordonii 13  
S. salivarius (-)  
S. sanguinis 13  
Table 1. 
7. Conclusion  
With the growing recognition of their benefits for public health in recent years, natural 
foods are now being highlighted with special reference to their effects on human health in 
addition to their pharmacological actions. Japanese Ume has been used as a herbal medicine 
with several biological activities, including anticancer, antioxidant and anti-inflammation 
effects (Nakagawa et al., 2007; Adachi et al., 2007; Okada et al., 2007; Mori et al.,2007; 
Kawahara et al., 2009). 
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MK615, an extract of compounds from Japanese Ume, has not only anti-inflammatory effects 
for periodontal tissues but also antimicrobial activity against periodontal bacteria, such as A. 
actinomycetemcomitans and P. gingivalis. In addition, MK615 exerted antibacterial activity 
against cariogenic bacteria, such as S. mutans, S. gordonii and S. sanguinis, with an expected 
anti-caries effect. Moreover, it was found that MK615 exhibited an inhibitory effect on S. 
mutans biofilm formation. MK615 has potential as a therapeutic agent for treating and 
preventing oral diseases such as periodontitis and dental caries. Further studies will focus 
on the active anti-inflammatory and antimicrobial components in MK615, which should be 
identified and investigated for their mechanisms. 
MK615 is safe in food for providing health benefits, and this remains unquestioned even 
when it is prescribed for oral therapy. Moreover, it is also used as a treatment for patients 
with liver cancer. In the future, it may be added to toothpastes, mouth rinses and other oral 
products that can be used easily by the majority of the populationranging from youngsters 
to the elderly. In addition, MK615 may be applicable to the total body through examining its 
possible effects on not only oral bacteria but also Staphylococcus aureus and Candida albicans. 
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